China-based Kexing Pharmaceutical (SHA: 688136) has entered into a commercialization cooperation agreement with fellow Chinese firm Shandong Boan Biotechnology Co., Ltd (HKG: 6955). The partnership aims to promote the marketing and sales of Shandong Boan’s biosimilars BA6101 and BA1102 in Hong Kong and Macau. BA6101 is a biosimilar version of Amgen’s (NASDAQ: AMGN) Prolia (denosumab), while BA1102 is a biosimilar version of Xgeva.
Background on Denosumab and Biosimilars
Denosumab, a novel RANKL inhibitor developed by Amgen, is currently marketed in China by BeiGene. The 120mg dosage form, sold under the trade name Xgeva, was approved in China in May 2019. The 60mg dosage form, marketed as Prolia for the treatment of bone loss (osteoporosis) in at-risk patients, received approval in June 2020. Shandong Boan’s biosimilars, BA6101 and BA1102, were approved in China in December 2022 and May 2024, respectively.
Expanding Market Reach for Biosimilars
This commercialization agreement between Kexing Pharmaceutical and Shandong Boan Biotechnology will enhance the availability of these biosimilars in the Hong Kong and Macau markets, providing patients with more accessible treatment options for conditions such as osteoporosis and bone metastases.-Fineline Info & Tech
Leave a Reply